SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-26-005642 to BullFrog AI Holdings, Inc. (BFRG)

BullFrog AI Holdings, Inc.
Date: June 4, 2026 · CIK: 0001829247 · Accession: 0000000000-26-005642

Offering / Registration Process Regulatory Compliance Financial Reporting

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-296363

Date
June 4, 2026
Author
Vininder Singh
Form
UPLOAD
Company
BullFrog AI Holdings, Inc.

Letter

June 4, 2026 Vininder Singh Chief Executive Officer BullFrog AI Holdings, Inc. 325 Ellington Blvd, Unit 317 Gaithersburg, MD 20878 Re: BullFrog AI Holdings, Inc. Registration Statement on Form S-1 Filed May 29, 2026 File No. 333-296363 Dear Vininder Singh: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Peter Jaslow, Esq.

Show Raw Text
June 4, 2026
Vininder Singh
Chief Executive Officer
BullFrog AI Holdings, Inc.
325 Ellington Blvd, Unit 317
Gaithersburg, MD 20878
Re: BullFrog AI Holdings, Inc.
Registration Statement on Form S-1
Filed May 29, 2026
File No. 333-296363
Dear Vininder Singh:
 This is to advise you that we have not reviewed and will not review your registration
statement.
 Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
 Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Peter Jaslow, Esq.